Project Grant R01HL187341
Award Date 8/17/26
Completion Date 5/31/31
Dollars Obligated $625K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $198,728 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms of mitochondrial calcium extrusion in ischemic heart disease. The research focuses on TMEM65, an emerging target implicated in mitochondrial sodium-dependent calcium extrusion (MNCX). Ischemia-reperfusion injury damages cardiac tissue partly through aberrant mitochondrial...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $701,116 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate transcriptional mutagenesis as a novel mechanism driving heart failure. The research examines how oxidative stress promotes formation of 8-oxo-deoxyguanosine lesions in DNA, which disrupts transcriptional fidelity in cardiomyocytes. Aim 1 integrates long-read single-nucleus RNA sequencing from human heart...
- The National Heart, Lung, and Blood Institute awarded Michigan State University (Henry Ford Health+Michigan State University Health Sciences) $466,362 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the mechanisms by which mitochondrial calcium overload impairs cellular energy metabolism. The project uses cryo-electron microscopy and computational physiology to investigate how calcium sequestration regulates oxidative metabolism across multiple...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $1,088,692 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on interorganellar calcium signaling in health and disease. The award funds basic research examining how calcium signaling across the plasma membrane, endoplasmic reticulum, mitochondria, and lysosomes generates localized calcium microdomains that regulate transcriptional and metabolic programs...
- The National Heart, Lung, and Blood Institute awarded Baylor University $562,494 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026 for a Project Grant (R15HL179650) to identify metabolic drivers of cancer cachexia-associated cardiomyopathy. The research will use pre-clinical cancer cachexia mouse models to identify the role of mitochondrial dysfunction on metabolism and mechanical function in hearts and cardiac muscle cells from mice with cancer cachexia. Mice...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart Lung and Blood Institute awarded the Beckman Research Institute of the City of Hope $813,810 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on nucleotide supplementation as a treatment strategy for ischemic heart disease and myocardial infarction. The project investigates the role of nucleotide balance in cardiomyocyte proliferation and aims to apply these findings for cardiac repair using large animal models....
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $720,103 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of CLEC3B protein in vascular calcification associated with chronic kidney disease. The research examines how endothelial cell deficiency of Jagged1, a signaling molecule, contributes to arterial calcification through a downstream target protein called CLEC3B. The study uses mouse models of chronic...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $248,993 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop metasurface optical guidewires for treating coronary artery calcification during percutaneous coronary intervention. The award funds design and manufacture of sub-millimeter meta-surface optics for optical guidewires, development of optimized PCI workflows for laser-induced intravascular lithotripsy, and...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...